Biomarkers are emerging as the most essential tool to boost efficiency in the field of precision diagnostics and of drug target discovery. Around 90% of new chemical compounds fail during clinical trials. Biomarkers have the potential to decrease this by identifying potential drug failures at an early stage, as well as providing clinicians with a predictive tool for patient stratification, using conventional drugs. Thus, the advent of biomarker pattern profiling, rather than reliance on a single target, are set to improve results, by allowing patient stratification, integrated with pre-clinical diagnosis and target discovery.
By integrating cutting-edge technologies, with clinical needs, we believe that we will be able to develop better predictors by integrating:
- molecular profiling with clinical response
- functional in vitro studies of biological mechanisms mediating tumour progression with drug response
Based on leading high-throughput technology development, the CREATE Health Center of Translational Cancer Research will have a major impact on the way diseases will be diagnosed, treated and managed.
At CREATE Health we are focusing on the following diseases: Pancreatic cancer, breast cancer, colon cancer, leukemia, lymphoma, neuroblastoma, prostate cancer, ovarial cancer, malignant melanoma and kidney cancer.